secwatch.observer — SEC 8-K summary
======================================

Issuer:     GILEAD SCIENCES, INC. (GILD)
CIK:        0000882095
Form:       8-K
Filed at:   2026-02-10T23:59:59+00:00
Accession:  0000882095-26-000003
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gilead Q4/FY2025: revenue up 5% to $7.9B Q4, full-year EPS $6.78; guides 2026 sales $29.6-30B
--------------------------------------------------------------------------------

- Q4 GAAP diluted EPS $1.74 vs $1.42 YoY; non-GAAP diluted EPS $1.86 vs $1.90.
- Q4 product sales up 5% to $7.9B; HIV sales up 6% to $5.8B; Biktarvy $4.0B (+5%).
- Full year 2025 total revenues $29.4B (+2%); product sales ex-Veklury $28.0B (+4%).
- Full year GAAP diluted EPS $6.78 vs $0.38; non-GAAP $8.15 vs $4.62.
- FY2026 guidance: product sales $29.6-30B, non-GAAP diluted EPS $8.45-8.85.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882095/000088209526000003/0000882095-26-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882095/000088209526000003/gild-20260210.htm
  HTML page:      https://secwatch.observer/filing/0000882095-26-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer